Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

MedicalMinute: Recent Advances in Targeting HER2 and HER3 in Metastatic Gastrointestinal Cancers
  • CME
  • MOC

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
ABIM MOC: maximum of 0.5 Medical Knowledge MOC point(s)
Released: May 27, 2021 Expiration: May 26, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.
Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Daniel Catenacci, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review evidence-based guidelines and expert recommendations for assessing HER2 in the metastatic setting for gastrointestinal cancers
  • Appraise the available clinical data for established and emerging HER2- and HER3-targeted therapies in gastrointestinal cancers
  • Implement best practices for HER2 diagnostic testing and interpretation to guide integration of the latest targeted therapies into individualized treatment plans
  • Identify patients eligible to enroll on important ongoing clinical trials based on evaluating novel HER2- and HER3-targeted therapies in gastrointestinal cancers

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Mark D. Pegram, MD

Susy Yuan-Huey Hung Professor of Medical Oncology
Associate Director for Clinical Research
Stanford Comprehensive Cancer Institute
Director of Clinical Translational Research Unit
Associate Dean for Clinical Research Quality
Stanford University School of Medicine
Standford, California

Mark D. Pegram, MD, has disclosed that he has received consulting fees from AstraZeneca, Daiichi Sankyo, Roche/Genentech, and Seattle Genetics.
Michael F. Press, MD, PhD

Harold E. Lee Chair in Cancer Research
Professor of Pathology
Department of Pathology
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California

Michael F. Press, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Biocartis, Lilly, Merck, Novartis, Puma, and Zymeworks; has received funds for research support from Cepheid, Lilly, Novartis, Puma, and Zymeworks; and holds private equity in TORL Biotherapeutics.

Faculty

Daniel Catenacci, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Director, Center for Esophageal and Gastric Cancer
Associate Director, Gastrointestinal Oncology Program
University of Chicago
Chicago, Illinois

Daniel Catenacci, MD, has disclosed that he has received consulting fees from Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Ono, Pieris, QED, Seattle Genetics, Taiho, Tempus, and Zymeworks; and fees for non CME/CE services from AstraZeneca, Daiichi, Eli Lilly, Genentech/Roche, Guardant Health, Merck, and Tempus.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists, pathologists, and other healthcare professionals who care for patients with gastrointestinal cancers.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners in utilizing diagnostics to guide treatment of various HER2- and HER3-altered gastrointestinal cancers in the metastatic setting.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 27, 2021, through May 26, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

MedicalMinute: Recent Advances in Targeting HER2 and HER3 in Metastatic Gastrointestinal Cancers
  • CME
  • MOC

Loading...
This focused activity provides an expert’s perspective on the most clinically relevant data for approved and investigational therapies targeting HER2 and HER3 in advanced gastroesophageal and colorectal cancers.
Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Daniel Catenacci, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
ABIM MOC: maximum of 0.5 Medical Knowledge MOC point(s)
Released: May 27, 2021 Expiration: May 26, 2022

Related Content

Gain clinical insights quickly with this short slideset from Clinical Care Options (CCO) on key actionable biomarkers for GI cancers

David H. Ilson, MD, PhD John L. Marshall, MD Eric Van Cutsem, MD, PhD Released: July 23, 2021

From Clinical Care Options (CCO), video of pharmacist discussion of recently approved agents targeting HER2 and TROP2 for metastatic cancers

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Allison Butts, PharmD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 20, 2021 Expired: July 19, 2022

Slides from Clinical Care Options (CCO) on histology-agnostic biomarker testing to guide therapy for gastrointestinal cancer

John L. Marshall, MD Released: July 15, 2021

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and gastroesophageal cancers

David H. Ilson, MD, PhD Released: July 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue